Status:
COMPLETED
Study Design of 'Influence of Sarpogrelate in Patients With Renal Impairment or Diabetes Mellitus' Study
Lead Sponsor:
Seoul National University Bundang Hospital
Collaborating Sponsors:
Yuhan Corporation
Conditions:
Coronary Artery Disease
Diabetes Mellitus
Eligibility:
18+ years
Phase:
PHASE3
Brief Summary
The purpose of the SERENADE trial is to evaluate the safety and efficacy of sarpogrelate in patients with CKD or DM after DES implantation.
Detailed Description
The rates of stent failure after percutaneous intervention (PCI) have declined after introduction of the drug eluting stent (DES). However, chronic kidney disease (CKD) or diabetes mellitus (DM) still...
Eligibility Criteria
Inclusion
- symptomatic CAD (including acute coronary syndrome) or positive stress test and a native coronary lesion (\>50% diameter stenosis by visual estimation on coronary angiogram and reference diameter \> 2.5 mm)
- AND CKD or DM patients
Exclusion
- if they had contraindication to aspirin, clopidogrel or sarpogrelate.
Key Trial Info
Start Date :
April 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2014
Estimated Enrollment :
220 Patients enrolled
Trial Details
Trial ID
NCT02294643
Start Date
April 1 2009
End Date
March 1 2014
Last Update
November 25 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Bundang Hospital
Seongnam, South Korea, 463-707